
Context Therapeutics, a biotech company that focuses on the development of treatments for Sigma1-related diseases, has announced that a new …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

